Cassava Sciences Stock Plummets 85% After Phase III Study Failure
Cassava Sciences announced on November 25, 2024, that its Phase III ReThink-ALZ study failed to meet primary and secondary endpoints for treating mild to moderate Alzheimer's disease. The trial results indicated that Simufilam did not show superiority over a placebo in improving ADAS-COG12 and ADCS-ADL scores. This news led to an 85% drop in the company’s stock price. Since 2021, the efficacy of Simufilam in reducing β-amyloid protein toxicity has been questioned. Two scientists petitioned the FDA to suspend the trials, citing image manipulation in research papers. An NIH investigation report accused the developers of academic misconduct in multiple publications. FDA reviews found issues with data handling, including improper equipment calibration and inappropriate statistical testing. The researchers were indicted by the DOJ in June 2023 for allegedly defrauding NIH grants of approximately $16 million.
You May Interested In
2026-08-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
When the Skin of Ships Gets More Expensive: A 30% Price Shock Is Quietly Rewriting the Cost Floor of Global Shipping
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
Chemours Partners with SRF Limited to Enhance Fluoropolymer and Intermediates Portfolio
-
Ukraine Strikes Russia’s Perm Refinery Again, Forcing Crude Unit Offline at 260,000-BPD Facility
-
Global Chemical Giants Accelerate Plant Closures and Layoffs as Industry Enters Structural Capacity Rationalization
-
European Diesel Crack Spread Hits Record $74.66 per Barrel as Global Refinery Outages Mount
-
U.S. Chemical Companies Are Benefiting from This Feedstock Shock
-
Wanhua Chemical Raises Southeast Asia MDI and TDI Offers by $200 per Tonne
Recommend Reading
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
EU Authorises Propionic Acid and Its Salts as Feed Additives Until 2035
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Calcium Propionate Uses: Food Preservation & Industrial Applications
-
Price Cuts and Weak Demand Create Tension as October PC Prices Rise, Then Retreat
-
Fundamental Factors Fail to Deliver Positive Momentum; October ABS Prices Gradually Decline
-
In October, the Chinese marine fuel market trended downward with fluctuations